| Summary: | Background: We previously reported that interstitial injection of bleomycin (BLM) reduces the size of early-stage extracranial arteriovenous malformation (AVM). Here, we sought to investigate the potential mechanism of BLM in treating extracranial AVM. Methods: Samples of human extracranial AVM (n=3) with no pharmacological treatment were harvested. AVM endothelial cells were isolated and cultured in primary cell culture. The transcriptome was examined using RNA-sequencing, and differentially expressed C-type lectin domain family 14 member A (CLEC14A) was validated at the transcriptomic and protein levels. Immunocytochemical staining of CLEC14A was performed in samples of human extracranial AVM, with and without BLM treatment. Results: Through second-generation sequencing, we found that the expression of 5 689 genes were differentially increased or decreased following 24-h BLM stimulation. We found that CLEC14A may play an important role in the progression of AVM and can be inhibited by BLM treatment. Conclusion: BLM inhibited CLEC14A expression to attenuate the progression of AVM.
|
|---|